Advances in Purification & Recovery
Optimizing Downstream Efficiency
8/12/2026 - August 13, 2026 ALL TIMES EDT
Purification and recovery strategies are evolving rapidly to keep pace with an increasingly diverse biologics pipeline. This conference brings together purification scientists and process engineers to address the full scope of downstream challenges — from the purification of bispecific antibodies, novel formats, and hexameric IgGs, to AAV vectors and extracellular vesicles. Sessions will also highlight innovation in chromatography platform development, and the growing role of mechanistic modelling and automation in accelerating purification process design.
Preliminary Agenda

Session Block

PLENARY SESSION

PLENARY KEYNOTE PRESENTATION:
The Correct Way to Bring Digitalization and AI into Biopharmaceutical Quality

Photo of Anthony R. Mire-Sluis, PhD, Senior Vice President, Global Quality, Gilead Sciences , SVP , Global Quality , Gilead Sciences
Anthony R. Mire-Sluis, PhD, Senior Vice President, Global Quality, Gilead Sciences , SVP , Global Quality , Gilead Sciences

Digitalizing quality systems and artificial intelligence could revolutionize the way we work in quality. However, it needs careful planning and execution to gain the maximum benefits to the business. Appropriate use cases, change management, training, and streamlining processes before you digitalize is essential—adding complexity just results in digital complexity. In addition, the implementation of AI must follow GxP principles in what is currently a vague regulatory framework.

Panel Moderator:

PANEL DISCUSSION:
Fireside Chat with Audience Q & A

Photo of Susan Hynes, Global Head of Quality, GSK , SVP, GSK Global Quality , GSK
Susan Hynes, Global Head of Quality, GSK , SVP, GSK Global Quality , GSK

Panelists:

Photo of Lynn Bottone, Senior Vice President, Quality Operations, Environment Health & Safety, Pfizer Inc. , Senior Vice President Quality, Safety & Environmental Operations , Quality Operations, Environment Health & Safety , Pfizer Inc
Lynn Bottone, Senior Vice President, Quality Operations, Environment Health & Safety, Pfizer Inc. , Senior Vice President Quality, Safety & Environmental Operations , Quality Operations, Environment Health & Safety , Pfizer Inc
Photo of Anthony R. Mire-Sluis, PhD, Senior Vice President, Global Quality, Gilead Sciences , SVP , Global Quality , Gilead Sciences
Anthony R. Mire-Sluis, PhD, Senior Vice President, Global Quality, Gilead Sciences , SVP , Global Quality , Gilead Sciences

Session Block

PURIFICATION FOR EMERGING MODALITIES

Low Molecular Weight (LMW) Species Control in Bispecific Antibody Purification Process

Photo of Lingling Xia, PhD, Principal Research Scientist I, Purification Process Development—ADC, PDS&T-BDL, AbbVie Inc. , Principal Research Scientist I, Purification Process Development - ADC , PDS&T - BDL , AbbVie Inc
Lingling Xia, PhD, Principal Research Scientist I, Purification Process Development—ADC, PDS&T-BDL, AbbVie Inc. , Principal Research Scientist I, Purification Process Development - ADC , PDS&T - BDL , AbbVie Inc
Photo of Nicholas Delatorre, Principal Scientist, CMC, Third Arc Bio , Principal Scientist , CMC , Third Arc Bio
Nicholas Delatorre, Principal Scientist, CMC, Third Arc Bio , Principal Scientist , CMC , Third Arc Bio
Photo of Yanhuai (Richard) Ding, PhD, Senior Director, CMC DS/DP, EvolveImmune Therapeutics , Sr. Director, CMC DS/DP , CMC , EvolveImmune Therapeutics
Yanhuai (Richard) Ding, PhD, Senior Director, CMC DS/DP, EvolveImmune Therapeutics , Sr. Director, CMC DS/DP , CMC , EvolveImmune Therapeutics
Photo of Albert Kao, Senior Scientist, Purification Development, Genentech, Inc. , Senior Scientist , Purification Development , Genentech, Inc.
Albert Kao, Senior Scientist, Purification Development, Genentech, Inc. , Senior Scientist , Purification Development , Genentech, Inc.
Photo of Tomas Mesurado, PhD Student, Acib GmbH , PhD Student , Bioprocess Engineering , Acib GmbH
Tomas Mesurado, PhD Student, Acib GmbH , PhD Student , Bioprocess Engineering , Acib GmbH
Photo of Rujin Cheng, PhD, Principal Scientist, Biotherapeutics, ImmunEdge , Principal Scientist , Biotherapeutics , ImmunEdge
Rujin Cheng, PhD, Principal Scientist, Biotherapeutics, ImmunEdge , Principal Scientist , Biotherapeutics , ImmunEdge

Hexameric IgGs are a class of complex biologics that offers unique pharmacokinetics and pharmacodynamic properties due to their high valency (up to 12 antigen binding sites), molecular weight (~900 kDa), or hydrodynamic radius. Despite their attractive profile for certain therapeutic indications, technical challenges in purification and analytics hinder their broader application. This talk aims to demystify some of the challenges by providing comprehensive molecule analysis/illustration and a couple of successful examples where key problems are identified and resolved. It would be of some guidance or introduction for those who are interested in making large and complex biologics for drug discovery and development.

NEXT-GENERATION CHROMATOGRAPHY

KEYNOTE PRESENTATION: Next-Generation Cation Exchange Chromatography Platform Process Development for Biologics Purification

Photo of Lihua Yang, PhD, Senior Prinicpal Research Scientist, BioProcess Purification Development, AbbVie, Inc. , Senior Principal Research Scientist , Bioprocess Purification Development , AbbVie Inc
Lihua Yang, PhD, Senior Prinicpal Research Scientist, BioProcess Purification Development, AbbVie, Inc. , Senior Principal Research Scientist , Bioprocess Purification Development , AbbVie Inc

This study evaluated five cation exchange (CEX) resins using three mAbs to identify optimal resins and develop a CEX process with superior dynamic binding capacity (DBC), impurity clearance, recovery yield, and robustness. In addition to experimental approaches, a mechanistic model was utilized to streamline the programming process as well as offering the potential to significantly reduce or even replace labor-intensive laboratory experiments in future process development.

Chromatographic Control of dsRNA Impurities Using a Mixed Mode Method with Platform Potential

Photo of Sabeen Nadir, Scientist, Pfizer Inc. , Scientist , Pfizer Inc
Sabeen Nadir, Scientist, Pfizer Inc. , Scientist , Pfizer Inc
Photo of Lukas Bongers, PhD Student, Gene Therapy Technical R&D, Roche Diagnostics GmbH , PhD Student , Gene Therapy Technical R&D , Roche Diagnostics GmbH
Lukas Bongers, PhD Student, Gene Therapy Technical R&D, Roche Diagnostics GmbH , PhD Student , Gene Therapy Technical R&D , Roche Diagnostics GmbH
Photo of Thomas F. Johnson, PhD, Lecturer, Biochemical Engineering, University College London , Senior Research Fellow , Biochemical Engineering , University College London
Thomas F. Johnson, PhD, Lecturer, Biochemical Engineering, University College London , Senior Research Fellow , Biochemical Engineering , University College London

3D printed chromatography columns provide advantages over conventional packed bed resins, in particular, control over the multiscale structure that can be tailored to the needs of the separation. However, possible disparities between design and fabricated columns lessens this benefit. We apply 3D imaging to evaluate and compare printed structures to original CAD files to refine the design process, creating more effective separation capabilities for emergent biological products.

APPLICATION OF MECHANISTIC MODELING AT VARIOUS DOWNSTREAM STAGES

Applied Automation and Mechanistic Modeling for Purification Development of Challenging Molecules under Accelerated Timelines

Photo of Scott H. Altern, PhD, Senior Scientist I, AbbVie Inc. , Sr Scientist I , AbbVie Inc
Scott H. Altern, PhD, Senior Scientist I, AbbVie Inc. , Sr Scientist I , AbbVie Inc
Photo of Spyridon Konstantinidis, PhD, Principal Scientist, Merck , Principal Scientist , Merck
Spyridon Konstantinidis, PhD, Principal Scientist, Merck , Principal Scientist , Merck
Photo of Chadakarn Sirasitthichoke, PhD, Senior Process Engineer, MS&T Systems and Engineering, Bristol Myers Squibb Co. , Senior Process Engineer , MS&TSystems and Engineering , Bristol Myers Squibb Co
Chadakarn Sirasitthichoke, PhD, Senior Process Engineer, MS&T Systems and Engineering, Bristol Myers Squibb Co. , Senior Process Engineer , MS&TSystems and Engineering , Bristol Myers Squibb Co

Adequate mixing and buffer exchange during ultrafiltration/diafiltration (UF/DF) are critical for robust downstream bioprocess performance, particularly when mechanical agitation is constrained by equipment or operating limits. In this study, computational fluid dynamics (CFD) modeling was applied to evaluate hydrodynamics, mixing efficiency, and buffer exchange performance in a large-scale UF/DF vessel operated without active agitation during diafiltration.


For more details on the conference, please contact:

Mimi Langley

Executive Director, Conferences

Cambridge Healthtech Institute

Email: mlangley@healthtech.com

 

For sponsorship information, please contact:

 

Companies A-K

Phillip Zakim-Yacouby

Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-247-1815

Email: philzy@cambridgeinnovationinstitute.com

 

Companies L-Z

Aimee Croke

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-292-0777

Email: acroke@cambridgeinnovationinstitute.com